Health Canada
Symbol of the Government of Canada
Consumer Product Safety

Re-evaluation Note REV2012-06, Re-evaluation Update Clofentezine

Pest Management Regulatory Agency
26 September 2012
ISSN: 1925-0649 (PDF version)
Catalogue number: H113-5/2012-6E-PDF (PDF version)

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

In Canada, clofentezine is under re-evaluation by Health Canada's Pest Management Regulatory Agency (PMRA). The PMRA's pesticide re-evaluation program considers potential risks as well as the value of pesticide products to ensure they continue to meet standards of modern science and current policy established to protect human health and the environment. This Re-evaluation Note is an update on the re-evaluation status of clofentezine.

Clofentezine is an acaricide, registered in Canada since 1989, used to control specific mite species in the egg stage and early larval stages. The end-use produ ct is registered to control European red mite, two-spotted spider mite and McDaniel spider mite on apple and pear, European red mite and two-spotted spider mite on peaches and nectarines and two-spotted spider mite on raspberries, strawberries and outdoor deciduous nursery stock (Use-Site Categories 13, 14 and 27). The product is formulated as a liquid to be applied by ground equipment by farmers and farm workers.

The Next link will take you to another Web site United States Environmental Protection Agency (USEPA) is also re-evaluating clofentezine as part of its registration review program and has published a final registration review work plan.Footnote 1 The PMRA will be working cooperatively with the USEPA on the re-evaluation of clofentezine and the overall Canadian re-evaluation timelines will be closely aligned with those of the USEPA.

The project plan discussed below outlines the anticipated areas of focus and risk assessments required to complete the re-evaluation of clofentezine. Should additional information become available during the re-evaluation period that affects the regulatory status of clofentezine, the PMRA will reconsider the area(s) of focus and risk assessments required.

Re-evaluation Project Plan

Human Health Assessment

  • The toxicological database and endpoints for risk assessment have been reviewed recently and do not require further assessment. Therefore, this component of the re-evaluation is considered to be complete.
  • The PMRA is currently conducting new assessments relating to occupational (mixer/loader/applicator and post application) and dietary exposure and will continue to work cooperatively with the USEPA.

Environmental Risk Assessment

  • The PMRA is currently conducting new assessments and will continue to work cooperatively with the USEPA. These assessments will include calculations for buffer zones.
  • Additional data are required to complete the assessment and a data call-in was issued under the authority of section 19 of the Next link will take you to another Web site Pest Control Product Act in 2009. As of June 2011, data were submitted and are currently under review.

Chemistry

  • A reassessment of the chemistry database of technical grade clofentezine has been completed.

Anticipated Timeline for Re-evaluation

  • A proposed re-evaluation decision for clofentezine is anticipated to be published for consultation in 2013.

Additional Information

If there are any questions or for additional information regarding the project plan, please contact Publications.

PMRA documents can be found on our website at healthcanada.gc.ca/pmra or through the Pest Management Information Service.

Footnotes

Footnote 1

United States Environmental Protection Agency, Clofentezine Final Work Plan for Registration Review, August 2007 (Docket ID: EPA-HQ-OPP-2006-0240).

Return to footnote 1 referrer